Powered by

Santhera Enters into Agreement to Acquire Option from Idorsia for Exclusive Sub-License of First-in-class Dissociative Steroid Vamorolon

Nov 20, 2018 - Thomson Reuters ONE

Santhera Pharmaceuticals Holding AG / Santhera Enters into Agreement to Acquire Option from Idorsia for Exclusive Sub-License of First-in-class Dissociative Steroid Vamorolon . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement.

- Vamorolone in clinical development for Duchenne muscular dystrophy (DMD) by ReveraGen BioPharma Inc. - pivotal VISION-DMD Phase IIb study ongoing

- Vamorolone has the potential to become stan...